Spero Therapeutics, Inc. (SPRO)
2.17
-0.04
(-1.81%)
USD |
NASDAQ |
Feb 27, 16:00
2.17
0.00 (0.00%)
After-Hours: 20:00
Spero Therapeutics Cash from Financing (TTM) : 0.00 for Sept. 30, 2025
Cash from Financing (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Financing (TTM) Benchmarks
| BioMarin Pharmaceutical, Inc. | -42.39M |
| Amicus Therapeutics, Inc. | 0.61M |
| Cassava Sciences, Inc. | 1.008M |
| Alpha Teknova, Inc. | 0.201M |
| Pyxis Oncology, Inc. | 0.054M |